On Monday, December 2, the next meeting of the Transparency Council.
The agenda includes:
1 Prepare a position paper on the evaluation of the drug Reagila (cariprazinum) for the indication: schizophrenia in adult patients after ineffectiveness or in case of contraindications to therapy with other second-generation antipsychotic drugs.
2. Preparation of a position paper on the evaluation of the drug Tolutris (telmisartanum + amlodipini besilas + hydrochlorothiazidum) for the indication: in replacement therapy for the treatment...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
